Microbot Medical launches limited U.S. commercial release of LIBERTY robotic system

Microbot Medical Inc.

LIBERTY Endovascular Robotic System now commercially available in U.S. on a limited basis after FDA 510(k) clearance in September 2025.
Limited Market Release (LMR) targets high procedure volume regions with existing preliminary demand; Full Market Release (FMR) planned for April 2026 at Society of Interventional Radiology meeting.
Company has hired core commercial team and secured third-party logistics partner to support the launch.
CEO Harel Gadot states the launch marks entry into commercialization phase, building a new robotic category with single-use system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.